Immix Biopharma is trading 5.43% down now at $9.68, with no clear company-specific announcement dated October 2 explaining the decline.
- Recent coverage points to lingering pressure after the company priced and closed a $125 million stock offering, adding dilution concerns; this is prior context, not a confirmed catalyst for today’s move.
- The broader market is higher: the S&P 500 is up 0.67% and the Nasdaq is up 1.09%, so the decline does not appear to track the market’s direction.